INT'L GROUP(SZ:000411)2022-04-19 16:00Financial Performance - The company reported a significant increase in revenue, with a year-on-year growth of 15% in 2021[13]. - The company's operating revenue for 2021 was CNY 26,730,979,470.50, representing a 6.89% increase compared to CNY 25,008,204,653.82 in 2020[18]. - The net profit attributable to shareholders for 2021 was CNY 167,809,938.17, up 7.06% from CNY 156,748,016.89 in 2020[18]. - The total revenue for 2021 was ¥26,730,979,470.50, representing a year-on-year increase of 6.89% compared to ¥25,008,204,653.82 in 2020[52]. - The net profit for 2021 reached ¥396,133,198.14, marking a 15.55% increase from ¥342,810,991.64 in 2020[52]. - The company reported a basic earnings per share of CNY 0.67 for 2021, a 6.35% increase from CNY 0.63 in 2020[18]. - The company anticipates a revenue growth forecast of 18% for the upcoming fiscal year, driven by new product launches and market expansion efforts[13]. - The company provided a positive outlook for the next fiscal year, projecting a revenue growth of 20% based on new product launches and market expansion strategies[129]. Dividend and Shareholder Returns - The company plans to distribute a total cash dividend of CNY 51,075,230, with a bonus share distribution of 2 shares for every 10 shares held[4]. - The profit distribution plan includes a cash dividend of ¥2.00 per 10 shares, with a total share base of 255,376,150 shares[150]. - The cash dividend payout ratio for the year was 30.44%[150]. - The company plans to increase capital by issuing 2 additional shares for every 10 shares held, resulting in a total share capital increase of 51,075,230 shares[151]. Market Expansion and Strategy - The company is focusing on expanding its market presence, particularly in the healthcare sector, aiming for a 20% increase in market share by 2023[13]. - The company is actively exploring new business models, including internet hospitals and pharmacies, to better serve public health needs in the post-pandemic era[48]. - The company aims to become the leading pharmaceutical distributor in Zhejiang Province, focusing on core pharmaceutical distribution as the main profit driver[99]. - The company plans to enhance its business layout by integrating pharmaceutical distribution with internet services, aiming for innovative development and ecological collaboration[98]. - The company is exploring potential mergers and acquisitions to enhance its market position[127]. Research and Development - The company has initiated the development of new products, including a line of herbal medicines expected to launch in Q3 2022[13]. - The company has introduced over 40 new products, including imported patented drugs and innovative domestic products in the fields of immunology and oncology in 2021[47]. - The company is investing in new technologies to improve operational efficiency, with a budget allocation of CNY 50 million for 2022[13]. - Research and development expenses surged by 324.87% to ¥8,564,100.98, primarily due to the development of new warehouse and transportation management systems[52]. - The company is actively engaging in research and development to innovate and meet market demands[129]. Risk Management - The company has identified key risk factors in its management discussion, including regulatory changes and market competition, and is implementing strategies to mitigate these risks[4]. - The company emphasizes strict compliance with drug quality management to mitigate risks related to product quality and potential economic losses[101]. - The company is implementing effective cash flow management strategies to address liquidity and accounts receivable risks as its business scales up[103]. Corporate Governance - The company has maintained a focus on the interests of minority shareholders during decision-making processes[137]. - The company’s board of directors is responsible for the appointment and evaluation of senior management, ensuring accountability and performance assessment[158]. - The company has established a transparent and effective incentive mechanism for senior management, linking performance directly to compensation[158]. - The company has committed to continuous improvement in its governance and operational strategies[137]. Community Engagement and Social Responsibility - The company has committed to supporting over 70% of provincial medical supplies during the COVID-19 pandemic, demonstrating its responsibility in public health[171]. - The company has signed a donation agreement for poverty alleviation with a local village, supporting economic development and local agriculture[172]. - The company actively promoted green initiatives, including energy-saving training and the use of solar energy in operations[169]. Operational Efficiency - The company is focusing on the development of new technologies and products to drive future growth[123]. - The company is enhancing talent development by promoting a younger and more professional workforce and implementing a tiered talent training plan[106]. - The company has a strong commitment to compliance and risk management, ensuring sustainable business practices[126].